On March 23, 2026, Pulse Biosciences, Inc. announced that its Compensation Committee awarded Chief Technology Officer Darrin R. Uecker a grant of restricted stock units representing 100,000 shares of the company's common stock, par value $0.001. This grant is part of the company's strategy to incentivize leadership in product development, particularly for the treatment of atrial fibrillation. The stock units will vest in full on the third anniversary of the grant date, contingent upon the terms outlined in the grant award agreement and the company's Amended and Restated 2017 Equity Incentive Plan. This move is seen as a positive step in retaining key leadership talent and aligning their interests with those of shareholders, potentially leading to enhanced operational execution and strategic growth in the company's product offerings.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.